TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Release of Mayo Pathology Report Would Be Needed To Confirm Stage IIA Diagnosis. October 24, 2008
TCL Archive DCBD Board Approved Concepts For New Grants In Cytogenetics Solid Tumor Diagnoses December 13, 1984
TCL Archive In Brief: Harkin Proposes To Add Another $400 Million To NCU Budget, Money To Come Forom Defense July 26, 1991
